<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01056809</url>
  </required_header>
  <id_info>
    <org_study_id>PGC-8</org_study_id>
    <nct_id>NCT01056809</nct_id>
  </id_info>
  <brief_title>Treatment Strategies for Primarily Generalized Colorectal Cancer</brief_title>
  <acronym>PGC</acronym>
  <official_title>Treatment Strategies for Primarily Generalized Colorectal Cancer Prospective Randomized Comparison Between Two Treatment Strategies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vrinnevi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical Research Council of Southeast Sweden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vrinnevi Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      For patients with primarily generalized colorectal cancer two treatment strategies are
      compared to establish which strategy gives best overall survival.

      The traditional strategy is to first resect the primary colorectal tumour and then treat the
      metastases with chemotherapy followed if possible by surgery.

      The alternative strategy is to first treat the metastases with chemotherapy followed if
      possible by surgery and only resect the primary colorectal tumour if there is hope for cure
      or if symptoms develop that necessitates treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients are randomized between the two treatment strategies mentioned above. After initial
      treatment the patients are categorized as palliative or treated with curative intent.
      Patients are followed with quality of life evaluations every 6 months. Outpatient visits,
      hospital care, examinations and treatment are recorded as well as complications and side
      effects. Survival is recorded and for those patients treated with curative intent the tumour
      situation 3 years after randomization is evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Too slow recruitment
  </why_stopped>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years after completion of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>3 year survival for patients treated with curative intent</measure>
    <time_frame>3 years after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Palliative patients not receiving chemotherapy treated with the traditional strategy</measure>
    <time_frame>Completion of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Every 6 months up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health care consumption</measure>
    <time_frame>Completion of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications and side effects</measure>
    <time_frame>Completion of study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Traditional strategy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>First resection of the primary colorectal tumour, then treatment of metastases with chemotherapy and if possible surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alternative strategy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>First treatment of metastases with chemotherapy and if possible surgery, later resection of primary colorectal tumour if hope for cure or if symptoms develope that necessitates treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Chemotherapy and surgery</intervention_name>
    <description>Treatment not specified but in accordance with national guidelines</description>
    <arm_group_label>Traditional strategy</arm_group_label>
    <arm_group_label>Alternative strategy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with primarily generalized colorectal cancer diagnosed by pathology or
             typical appearance on x-ray or at endoscopy and where there is uncertainty regarding
             best treatment strategy

        Exclusion Criteria:

          -  Patients not willing to participate or unable to sign informed consent.

          -  Patients with other malignancy with metastatic potential

          -  Patients where synchronous resection of primary tumour and metastases is planned

          -  Patients not fit for chemotherapy or surgery

          -  Patients with locally unresectable primary tumours

          -  Patients with symptoms from primary colorectal tumour necessitating resection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gunnar Arbman, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Surgery in Östergötland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Per Sandström, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Surgery in Östergötland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hans Starkhammar, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Regional Oncologic Center, Linköping</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bengt Glimelius, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>University of Uppsala, The Karolinska University Hospital, Stockholm</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lars Lundell, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>The Karolinska University Hospital, Stockholm</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Per-Olof Nyström, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>The Karolinska Universtiy Hospital, Stockholm</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ulf Gunnarsson, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>The Karolinska University hospital, Stockholm</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lars Påhlman, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>University of Uppsala</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Höglandssjukhuset</name>
      <address>
        <city>Eksjö</city>
        <zip>SE 57581</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Surgery</name>
      <address>
        <city>Gävle - Hudiksvall</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Länssjukhuset Ryhov</name>
      <address>
        <city>Jönköping</city>
        <zip>SE 55185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Länssjukhuset</name>
      <address>
        <city>Kalmar</city>
        <zip>SE 39185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitetssjukhuset</name>
      <address>
        <city>Linköping</city>
        <zip>SE 58185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vrinnevisjukhuset</name>
      <address>
        <city>Norrköping</city>
        <zip>SE 601 82</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska Universitetssjukhuset</name>
      <address>
        <city>Stockholm</city>
        <zip>SE 17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akademiska sjukhuset</name>
      <address>
        <city>Uppsala</city>
        <zip>SE 75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Värnamo sjukhus</name>
      <address>
        <city>Värnamo</city>
        <zip>SE 33185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrallasarettet</name>
      <address>
        <city>Västerås</city>
        <zip>SE 72189</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Mentha G, Majno PE, Andres A, Rubbia-Brandt L, Morel P, Roth AD. Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary. Br J Surg. 2006 Jul;93(7):872-8.</citation>
    <PMID>16671066</PMID>
  </reference>
  <reference>
    <citation>Scoggins CR, Meszoely IM, Blanke CD, Beauchamp RD, Leach SD. Nonoperative management of primary colorectal cancer in patients with stage IV disease. Ann Surg Oncol. 1999 Oct-Nov;6(7):651-7.</citation>
    <PMID>10560850</PMID>
  </reference>
  <reference>
    <citation>Benoist S, Pautrat K, Mitry E, Rougier P, Penna C, Nordlinger B. Treatment strategy for patients with colorectal cancer and synchronous irresectable liver metastases. Br J Surg. 2005 Sep;92(9):1155-60.</citation>
    <PMID>16035135</PMID>
  </reference>
  <reference>
    <citation>Scheer MG, Sloots CE, van der Wilt GJ, Ruers TJ. Management of patients with asymptomatic colorectal cancer and synchronous irresectable metastases. Ann Oncol. 2008 Nov;19(11):1829-35. doi: 10.1093/annonc/mdn398. Epub 2008 Jul 28. Review.</citation>
    <PMID>18662955</PMID>
  </reference>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2010</study_first_submitted>
  <study_first_submitted_qc>January 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2010</study_first_posted>
  <last_update_submitted>May 30, 2012</last_update_submitted>
  <last_update_submitted_qc>May 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 31, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vrinnevi Hospital</investigator_affiliation>
    <investigator_full_name>Gunnar Arbman</investigator_full_name>
    <investigator_title>Consultant surgeon</investigator_title>
  </responsible_party>
  <keyword>Colorectal cancer</keyword>
  <keyword>Metastases</keyword>
  <keyword>Treatment strategies</keyword>
  <keyword>Colorectal cancer with synchronous metastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

